Marpai, Inc. Reports $4.6 Million Net Loss and 10.5% Revenue Decline in Q2 2026

Marpai, Inc. reported a net loss of $4.6 million for the second quarter of 2026, a slight increase from the $4.4 million loss recorded in the same period of the previous year. Revenue for the quarter decreased by 10.5% to $4.2 million, down from $4.7 million in Q2 2025. For the first half of 2026, total revenue was $8.6 million, reflecting a 14.5% decline compared to $10.1 million in the first half of 2025. The company attributed this decrease primarily to customer turnover, indicating a need to adapt its service offerings to better meet evolving market demands.

In terms of expenses, Marpai's total costs for the second quarter of 2026 were $7.6 million, down from $8.3 million in the prior year, marking an 8% reduction. The cost of revenue decreased by 19% to $3.2 million, driven by lower sales. However, general and administrative expenses rose by 23.6% to $3.1 million, reflecting increased investments in labor and operational support. The company also reported a significant increase in net interest expense, which rose to $1.2 million from $813,000, largely due to adjustments related to its obligations to AXA.

Operationally, Marpai's total assets decreased to $9.5 million as of June 30, 2026, down from $10.9 million at the end of 2025. The company’s accumulated deficit increased to approximately $123.2 million, and it reported negative working capital of $14.5 million. The company’s cash and cash equivalents stood at $138,000, indicating tight liquidity. Marpai has been financing its operations through loans and the issuance of convertible notes, but it continues to seek additional capital to support ongoing operations and investments.

Strategically, Marpai has made significant moves to restructure its financial obligations. On July 16, 2026, the company amended its purchase agreement with AXA, which included provisions for minimum annual payments and restrictions on incurring additional debt. Additionally, on July 29, 2026, Marpai entered into a securities purchase agreement for the issuance of 12,100 shares of newly designated Series A Preferred Stock, expected to generate gross proceeds of $12.1 million. This capital infusion is crucial for the company as it aims to stabilize its financial position and continue its operations.

Looking ahead, Marpai's management has expressed concerns regarding its liquidity and the ability to continue as a going concern. The company is actively exploring options for raising additional capital, which may include equity or debt financing. If these efforts are unsuccessful, Marpai may need to scale back operations or divest assets, which could significantly impact its business strategy and market position.